Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

denosumab

denosumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Prolia SOLUTION, SUBCUTANEOUS 60 mg/mL      
Xgeva SOLUTION, SUBCUTANEOUS 120 mg/1.7 mL      
VIEW MORE Bone Resorption Inhibitors
CLASS
922400
Comments:

Prolia medication guide

Xgeva and Prolia are restricted to outpatient areas.

Inpatient consideration, denosumab use in hypercalcemia urgency (not hypercalcemia of malignancy):  - Currently, little reliable information is available regarding the use of denosumab for hypercalcemia urgency related to parathyroid hormone abnormality.  This medication is relatively long acting, so clinical response could be delayed  (up to a week or longer for time to response and complete response seen out to 3+ weeks).  There is currently no criteria set or protocol for using denosumab in hypercalcemia urgency at Huntsville Hospital; use should be evaluated on a case by case basis. (Drug Info statement December 2022)

Reviewed: August 24, 2010 (Prolia) and March 22, 2011 (Xgeva)

REMS (Prolia): View FDA REMS Info

Last updated: Feb. 16, 2024






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved